E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Room 901, Building 2, No. 355, Xingzhong Road, Donghu Street, Linping District, Hangzhou, Zhejiang, China

Clinical Trials

2 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

42.9%

Phase 2

42.9%

Phase 3

14.3%

Trial Status Distribution

Completed

28.6%

Enrolling By Invitation

14.3%

Not yet recruiting

14.3%

Recruiting

42.9%

Clinical Trials

Trials sponsored by this organization (7)

A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo

Phase 2

Recruiting

interventional

Nov 2025200 participants

Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis

Phase 2

Completed

interventional

Jun 202524 participants

A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis.

Phase 3

Enrolling By Invitation

interventional

Mar 2025460 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations

E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (7)

A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo

Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis

A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis.

A Study of QY101 Ointment in Subjects With Plaque Psoriasis

A First-in-Human Study of QY211 Gel in Adult Subjects

A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis

A First-in-Human Study of QY101 Ointment in Adult Subjects

Approvals

News